Barclays
ELVN icon

Barclays’s Enliven Therapeutics ELVN Stock Holding History

Barclays’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.58M Buy
34,534
+13,718
+66% +$747K ﹤0.01% 2741
2026
Q2 		$1.06M Buy
20,816
+8,986
+76% +$381K ﹤0.01% 2762
2026
Q1 		$464K Sell
11,830
-58,045
-83% -$1.61M ﹤0.01% 3232
2025
Q4 		$1.08M Sell
69,875
-814
-1% -$16.2K ﹤0.01% 3380
2025
Q3 		$1.45M Sell
70,689
-2,095
-3% -$42.2K ﹤0.01% 3124
2025
Q2 		$1.46M Buy
72,784
+22,427
+45% +$425K ﹤0.01% 3086
2025
Q1 		$991K Sell
50,357
-14,206
-22% -$306K ﹤0.01% 3109
2024
Q4 		$1.45M Buy
64,563
+8,346
+15% +$216K ﹤0.01% 3123
2024
Q3 		$1.44M Buy
56,217
+42,012
+296% +$973K ﹤0.01% 3112
2024
Q2 		$332K Sell
14,205
-12,031
-46% -$253K ﹤0.01% 3286
2024
Q1 		$461K Sell
26,236
-15,842
-38% -$243K ﹤0.01% 3641
2023
Q4 		$582K Buy
42,078
+28,449
+209% +$348K ﹤0.01% 3786
2023
Q3 		$186K Sell
13,629
-1,198
-8% -$20.2K ﹤0.01% 3335
2023
Q2 		$303K Buy
14,827
+7,600
+105% +$154K ﹤0.01% 3042
2023
Q1 		$158K Buy
+7,227
New +$147K ﹤0.01% 3928

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return

Barclays's ELVN Position: Q3 2026 in Review

Barclays increased its Enliven Therapeutics (ELVN) stake by 66% in Q3 2026, buying an estimated $747K and bringing the position to 34,534 shares worth $1.58M. The position accounts for ﹤0.01% of the portfolio, ranked #2741.

Barclays first reported a position in ELVN in Q1 2023 and has held it in 15 quarters since. 76 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.

  • Barclays held 34,534 shares of Enliven Therapeutics worth $1.58M as of Q3 2026.
  • Barclays bought 13,718 Enliven Therapeutics shares in Q3 2026, an estimated $747K.
  • Enliven Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2741 holding.
  • Barclays first reported a position in Enliven Therapeutics in Q1 2023 and has held it in 15 quarters since.
  • 76 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.